Abstract 2200
Background
Bone metastases (BM) are common in patients with solid tumours, especially breast, prostate and lung cancer. Patients with BM may experience skeletal-related events (SRE) including pathological fractures and spinal cord compression. Bisphosphonates and denosumab, known as SRE preventive agents (SPA), are indicated for patients with BM and are recommended by ESMO guidelines. However, data on the clinical use of these agents are lacking. The aim of this study was to estimate the proportion of SPA- and SRE-naïve patients receiving SPA treatments at SRE preventive doses following BM diagnosis.
Methods
Adult patients with solid tumours, a record of BM and no record of SPA treatment or an SRE before the first-recorded BM were identified from March 2011 to June 2016 in the Danish National Patient Registry or Danish Cancer Registry. The proportion of patients receiving hospital-administered SPA, identified via the Health Services Database of the Central Denmark Region, was calculated over the 6-month period after their first-recorded BM diagnosis along with the 95% confidence interval (CI). Follow-up was until death or December 31, 2016.
Results
A total of 2,556 eligible patients were included (m/f 1501/1055; median age 70 years (IQR 63–77). SPA treatment was recorded for 822 (32%) patients, mainly before the development of an SRE (86%, n = 706), in contrast to post-SRE (14%, n = 116). Across all solid tumours, a greater proportion of younger than older patients received SPA treatment. Receipt of SPA before an SRE varied by cancer site: lung (50%, 95% CI 46%–54%), breast (42%, 95% CI 37%–47%), prostate (3%, 95% CI 2%–5%), and other solid tumours (20%, 95% CI 18%–23%). Median [IQR] time from first-recorded BM diagnosis to first SPA before an SRE also varied by cancer site: breast (22 [7, 51] days), lung (6 [3, 26] days), prostate (43 [17, 57] days) and other solid tumours (24 [5, 44] days).
Conclusions
In this descriptive study, variations in the use of SPA for SRE prevention in routine clinical settings were observed across different solid tumours, warranting further cancer-specific investigations while accounting for patients’ characteristics.
Clinical trial identification
Amgen study 20160169.
Editorial acknowledgement
Legal entity responsible for the study
Amgen (Europe) GmbH.
Funding
Amgen (Europe) GmbH through an institutional grant; administered by Aarhus University.
Disclosure
J. Acquavella: Shareholder / Stockholder / Stock options; JA retired from Amgen in 2014. A.M. Seesaghur: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen; Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. R.K. Hernandez: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. V. Ehrenstein: Full / Part-time employment; VE is a salaried employee of Aarhus University and has nothing to declare. All other authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract